282 related articles for article (PubMed ID: 8609056)
1. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Abe M
Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
[TBL] [Abstract][Full Text] [Related]
2. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
4. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
Minchinton AI; Brown JM
Br J Cancer; 1992 Dec; 66(6):1053-8. PubMed ID: 1457345
[TBL] [Abstract][Full Text] [Related]
6. In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation.
Sasai K; Fushiki M; Yukawa Y; Suyama S; Iwai H; Shibamoto Y; Nishimoto S; Takahashi M; Abe M
Int J Radiat Oncol Biol Phys; 1991 Oct; 21(5):1231-4. PubMed ID: 1938521
[TBL] [Abstract][Full Text] [Related]
7. Reoxygenation in the SCCVII tumor after KU-2285 sensitization plus single or fractionated irradiation.
Shibamoto Y; Kitakabu Y; Murata R; Oya N; Shibata T; Sasai K; Takahashi M; Abe M
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):583-6. PubMed ID: 8005819
[TBL] [Abstract][Full Text] [Related]
8. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Brown JM; Lemmon MJ
Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
[TBL] [Abstract][Full Text] [Related]
9. Reoxygenation and rehypoxiation in the SCCVII mouse tumor.
Kim IH; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):493-7. PubMed ID: 8005805
[TBL] [Abstract][Full Text] [Related]
10. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
Brown JM; Lemmon MJ
Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
[TBL] [Abstract][Full Text] [Related]
11. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice.
Iwai H; Matsuno E; Sasai K; Shibamoto Y; Abe M
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):591-4. PubMed ID: 8005821
[TBL] [Abstract][Full Text] [Related]
13. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Brown JM; Lemmon MJ
Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
[TBL] [Abstract][Full Text] [Related]
14. Exploring vascular dysfunction caused by tirapazamine.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Microvasc Res; 2008 Mar; 75(2):247-55. PubMed ID: 18023823
[TBL] [Abstract][Full Text] [Related]
15. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
Zeman EM; Brown JM; Lemmon MJ; Hirst VK; Lee WW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
[TBL] [Abstract][Full Text] [Related]
17. KIN-804 vs. KU-2285 as a radiosensitizer for clinical use.
Oya N; Shibamoto Y; Shibata T; Murata R; Iwai H; Sugiyama T; Abe M
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):595-600. PubMed ID: 8005822
[TBL] [Abstract][Full Text] [Related]
18. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
Dorie MJ; Kovacs MS; Gabalski EC; Adam M; Le QT; Bloch DA; Pinto HA; Terris DJ; Brown JM
Neoplasia; 1999 Nov; 1(5):461-7. PubMed ID: 10933062
[TBL] [Abstract][Full Text] [Related]
19. Carbogen breathing after irradiation enhances the effectiveness of tirapazamine in SiHa tumors but not SCCVII tumors in mice.
Minchinton AI; Tonn DA; Sutherland DP; Kyle AH
Radiat Res; 2002 Jul; 158(1):94-100. PubMed ID: 12071808
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
Zeman EM; Hirst VK; Lemmon MJ; Brown JM
Radiother Oncol; 1988 Jul; 12(3):209-18. PubMed ID: 3175048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
